{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:22:16Z","timestamp":1795029736850,"version":"4.10.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lundbeck LLC, Deerfield, IL, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The REVIEW study evaluated the real-world experiences of individuals treated with eptinezumab for chronic migraine (CM) in the outpatient setting. This post hoc analysis explored eptinezumab effectiveness in three participant subgroups: those who had self-reported psychiatric comorbidities, those previously treated with subcutaneous anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) for migraine prevention, or those who had reported ever experiencing symptoms of brain fog.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with a CM diagnosis who completed\u2009\u2265\u20092 eptinezumab infusion cycles provided survey responses that included the number of good days (participant-defined) per month before and after initiating eptinezumab, the presence\/absence of comorbid psychiatric conditions, the number and type of subcutaneous anti-CGRP mAbs used prior to initiating eptinezumab, and the presence\/absence of brain fog (feeling confused, difficulty learning\/remembering, or trouble speaking\/reading) and its improvement after initiating eptinezumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 94 participants, 61 (65%) reported psychiatric comorbidities, and 84 (89%) had previously used a subcutaneous anti-CGRP mAb. Average increase from baseline in participant-reported total number of good days per month after initiating eptinezumab were 9.8 and 10.1 days for those with the presence or absence of psychiatric conditions at baseline, respectively; based on the type of subcutaneous anti-CGRP mAb, average increase from baseline were, 9.2 days (erenumab), 10.6 days (fremanezumab), and 10.0 days (galcanezumab); and based on the number of prior mAbs, 9.9 days (0 prior), 8.9 days (1 prior), 11.7 days (2 prior), and 8.6 days (3 prior). Participants reporting complete\/very much improvement in brain fog had an average 15-day increase in the number of good days per month, while in participants that reported brain fog did not improve, there was a 1-day increase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This post hoc analysis of REVIEW showed that eptinezumab treatment can provide patient-perceived benefits across a spectrum of individuals with CM, including those with psychiatric comorbidities, in real-world settings. A greater number of good days regardless of number of prior mAb therapy supports the use of eptinezumab earlier for individuals with CM, rather than cycling through multiple anti-CGRP therapies. Furthermore, good days can provide a meaningful and measurable endpoint to assess preventive treatment and is correlated with improvements in brain fog.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-025-02165-2","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:20:59Z","timestamp":1764238859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world effectiveness of eptinezumab in chronic migraine\u2014increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog"],"prefix":"10.1186","volume":"26","author":[{"given":"Charles","family":"Argoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawad A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Soni-Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Wald","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foram","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"1","key":"2165_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E (2021) The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache 61(1):60\u201368. https:\/\/doi.org\/10.1111\/head.14024","journal-title":"Headache"},{"issue":"5","key":"2165_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","volume":"64","author":"F Cohen","year":"2024","unstructured":"Cohen F, Brooks CV, Sun D, Buse DC, Reed ML, Fanning KM et al (2024) Prevalence and burden of migraine in the United States: a systematic review. Headache 64(5):516\u2013532. https:\/\/doi.org\/10.1111\/head.14709","journal-title":"Headache"},{"key":"2165_CR3","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"10","key":"2165_CR4","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American migraine prevalence and prevention study. Headache 52(10):1456\u20131470. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02223.x","journal-title":"Headache"},{"key":"2165_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/head.13966","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB (2020) Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American migraine prevalence and prevention (AMPP) study. Headache. https:\/\/doi.org\/10.1111\/head.13966","journal-title":"Headache"},{"issue":"8","key":"2165_CR6","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM et al (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59(8):1286\u20131299. https:\/\/doi.org\/10.1111\/head.13613","journal-title":"Headache"},{"issue":"3","key":"2165_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31(3):301\u2013315. https:\/\/doi.org\/10.1177\/0333102410381145","journal-title":"Cephalalgia"},{"issue":"1","key":"2165_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01429-5","volume":"23","author":"SH Lo","year":"2022","unstructured":"Lo SH, Gallop K, Smith T, Powell L, Johnston K, Hubig LT et al (2022) Real-world experience of interictal burden and treatment in migraine: a qualitative interview study. J Headache Pain 23(1):65. https:\/\/doi.org\/10.1186\/s10194-022-01429-5","journal-title":"J Headache Pain"},{"issue":"8","key":"2165_CR9","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00415-012-6725-x","volume":"260","author":"DC Buse","year":"2013","unstructured":"Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260(8):1960\u20131969. https:\/\/doi.org\/10.1007\/s00415-012-6725-x","journal-title":"J Neurol"},{"issue":"7","key":"2165_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","volume":"87","author":"MT Minen","year":"2016","unstructured":"Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R et al (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87(7):741\u2013749. https:\/\/doi.org\/10.1136\/jnnp-2015-312233","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2165_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/head.13914","volume":"60","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Seng EK, Chu MK, Reed ML, Fanning KM, Adams AM (2020) The effect of psychiatric comorbidities on headache-related disability in migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 60(8):1683\u20131696. https:\/\/doi.org\/10.1111\/head.13914","journal-title":"Headache"},{"key":"2165_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2024.1409250","volume":"18","author":"A Alim-Marvasti","year":"2024","unstructured":"Alim-Marvasti A, Ciocca M, Kuleindiren N, Lin A, Selim H, Mahmud M (2024) Subjective brain fog: a four-dimensional characterization in 25,796 participants. Front Hum Neurosci 18:1409250. https:\/\/doi.org\/10.3389\/fnhum.2024.1409250","journal-title":"Front Hum Neurosci"},{"key":"2165_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/27706710.2024.2439437","author":"AK Choudhary","year":"2024","unstructured":"Choudhary AK (2024) Migraine and cognitive impairment: the interconnected processes. Brain-Apparatus Communication: A Journal of Bacomics. https:\/\/doi.org\/10.1080\/27706710.2024.2439437","journal-title":"Brain-Apparatus Communication: A Journal of Bacomics"},{"issue":"10","key":"2165_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14737175.2021.1947797","volume":"21","author":"D Vuralli","year":"2021","unstructured":"Vuralli D, Karatas H, Yemisci M, Bolay H (2021) Updated review on the link between cortical spreading depression and headache disorders. Expert Rev Neurother 21(10):1069\u20131084. https:\/\/doi.org\/10.1080\/14737175.2021.1947797","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"2165_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/head.14359","volume":"62","author":"W Lee","year":"2022","unstructured":"Lee W, Cho SJ, Hwang H, Lee M, Kim EH, Kim KM et al (2022) Crystal-clear days and unclear days in migraine: a population-based study. Headache 62(7):818\u2013827. https:\/\/doi.org\/10.1111\/head.14359","journal-title":"Headache"},{"issue":"3","key":"2165_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/head.14484","volume":"63","author":"MT Gerstein","year":"2023","unstructured":"Gerstein MT, Wirth RJ, Uzumcu AA, Houts CR, McGinley JS, Buse DC et al (2023) Patient-reported experiences with migraine-related cognitive symptoms: results of the micoas qualitative study. Headache 63(3):441\u2013454. https:\/\/doi.org\/10.1111\/head.14484","journal-title":"Headache"},{"issue":"3","key":"2165_CR17","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00415-014-7603-5","volume":"262","author":"R Gil-Gouveia","year":"2015","unstructured":"Gil-Gouveia R, Oliveira AG, Martins IP (2015) Assessment of cognitive dysfunction during migraine attacks: a systematic review. J Neurol 262(3):654\u2013665. https:\/\/doi.org\/10.1007\/s00415-014-7603-5","journal-title":"J Neurol"},{"issue":"10","key":"2165_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2020) Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 40(10):1026\u20131044. https:\/\/doi.org\/10.1177\/0333102420941839","journal-title":"Cephalalgia"},{"issue":"5","key":"2165_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M (2018) Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia"},{"issue":"1","key":"2165_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01764-9","volume":"25","author":"C Argoff","year":"2024","unstructured":"Argoff C, Herzog SP, Smith RM, Kotak SV, Sopina L, Saltarska Y et al (2024) Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: review, an observational, multi-site, US-based study. J Headache Pain 25(1):65. https:\/\/doi.org\/10.1186\/s10194-024-01764-9","journal-title":"J Headache Pain"},{"issue":"2","key":"2165_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/head.14817","volume":"65","author":"JS McGinley","year":"2025","unstructured":"McGinley JS, Mangrum R, Gerstein MT, McCarrier KP, Houts CR, Buse DC et al (2025) Symptoms across the phases of the migraine cycle from the patient\u2019s perspective: results of the MiCOAS qualitative study. Headache 65(2):303\u2013314. https:\/\/doi.org\/10.1111\/head.14817","journal-title":"Headache"},{"issue":"2","key":"2165_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/head.14664","volume":"64","author":"R Mangrum","year":"2024","unstructured":"Mangrum R, Bryant AL, Gerstein MT, McCarrier KP, Houts CR, McGinley JS et al (2024) The impacts of migraine on functioning: results from two qualitative studies of people living with migraine. Headache 64(2):156\u2013171. https:\/\/doi.org\/10.1111\/head.14664","journal-title":"Headache"},{"issue":"3","key":"2165_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43(3):1\u201314. https:\/\/doi.org\/10.1177\/03331024231152169","journal-title":"Cephalalgia"},{"issue":"4","key":"2165_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 43(4):1\u201314. https:\/\/doi.org\/10.1177\/03331024231159366","journal-title":"Cephalalgia"},{"issue":"9","key":"2165_CR25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45560","volume":"15","author":"MR Muddam","year":"2023","unstructured":"Muddam MR, Obajeun OA, Abaza A, Jaramillo AP, Sid Idris F, Anis Shaikh H et al (2023) Efficacy and safety of anti-calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies in preventing migraines: a systematic review. Cureus 15(9):e45560. https:\/\/doi.org\/10.7759\/cureus.45560","journal-title":"Cureus"},{"key":"2165_CR26","doi-asserted-by":"publisher","unstructured":"Talbot J, Stuckey R, Wood N, Gordon A, Crossingham G, Weatherby S (2024) Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab. Eur J Hosp Pharm 32(2):178\u201385. https:\/\/doi.org\/10.1136\/ejhpharm-2023-003779","DOI":"10.1136\/ejhpharm-2023-003779"},{"issue":"5","key":"2165_CR27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s13311-023-01394-0","volume":"20","author":"G Lambru","year":"2023","unstructured":"Lambru G, Caponnetto V, Hill B, Ratti S, Sacco S, Murphy M et al (2023) Long-term effect of switching from an anti-CGRP receptor to an anti-CGRP ligand antibody in treatment-refractory chronic migraine: a prospective real-world analysis. Neurotherapeutics 20(5):1284\u20131293. https:\/\/doi.org\/10.1007\/s13311-023-01394-0","journal-title":"Neurotherapeutics"},{"issue":"7","key":"2165_CR28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153S","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society (2021) The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021\u201339. https:\/\/doi.org\/10.1111\/head.14153S","journal-title":"Headache."},{"key":"2165_CR29","unstructured":"EMGALITY\u00ae (galcanezumab-gnlm) injection, for subcutaneous use (2025) Prescribing information. Eli Lilly and Company. https:\/\/emgality.lilly.com\/. Accessed 2 Oct 2025"},{"key":"2165_CR30","unstructured":"VYEPTI\u00ae (eptinezumab-jjmr) injection, for intravenous use (2025) Prescribing information. Lundbeck Seattle BioPharmaceuticals, Inc. https:\/\/www.vyepti.com\/.\u00a0Accessed 2 Oct 2025"},{"key":"2165_CR31","unstructured":"AJOVY\u00ae (fremanezumab-vfrm) injection, for subcutaneous use (2025) Prescribing information. Teva Pharmaceuticals USA, Inc. https:\/\/www.ajovy.com\/. Accessed 2 Oct 2025"},{"key":"2165_CR32","unstructured":"AIMOVIG\u00ae (erenumab-aooe) injection, for subcutaneous use\u00a0(2025) Prescribing information. Amgen Inc. https:\/\/www.aimovig.com\/.\u00a0Accessed 2 Oct 2025"},{"issue":"3","key":"2165_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208074","volume":"102","author":"RE Shapiro","year":"2024","unstructured":"Shapiro RE, Nicholson RA, Seng EK, Buse DC, Reed ML, Zagar AJ et al (2024) Migraine-related stigma and its relationship to disability, interictal burden, and quality of life: results of the OVERCOME (US) study. Neurology 102(3):e208074. https:\/\/doi.org\/10.1212\/WNL.0000000000208074","journal-title":"Neurology"},{"issue":"3","key":"2165_CR34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40120-023-00456-x","volume":"12","author":"E Gross","year":"2023","unstructured":"Gross E, Ruiz de la Torre E, Martelletti P (2023) The migraine stigma kaleidoscope view. Neurol Ther 12(3):703\u2013709. https:\/\/doi.org\/10.1007\/s40120-023-00456-x","journal-title":"Neurol Ther"},{"issue":"3","key":"2165_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/WCO.0000000000000309","volume":"29","author":"EK Seng","year":"2016","unstructured":"Seng EK, Seng CD (2016) Understanding migraine and psychiatric comorbidity. Curr Opin Neurol 29(3):309\u2013313. https:\/\/doi.org\/10.1097\/WCO.0000000000000309","journal-title":"Curr Opin Neurol"},{"key":"2165_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175222","author":"J Casas-Limon","year":"2024","unstructured":"Casas-Limon J, Quintas S, Lopez-Bravo A, Alpuente A, Andres-Lopez A, Castro-Sanchez MV et al (2024) Unravelling migraine stigma: a comprehensive review of its impact and strategies for change. J Clin Med 13(17). https:\/\/doi.org\/10.3390\/jcm13175222","journal-title":"J Clin Med"},{"issue":"5","key":"2165_CR37","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1177\/0333102411436333","volume":"32","author":"EK Seng","year":"2012","unstructured":"Seng EK, Holroyd KA (2012) Psychiatric comorbidity and response to preventative therapy in the treatment of severe migraine trial. Cephalalgia 32(5):390\u2013400. https:\/\/doi.org\/10.1177\/0333102411436333","journal-title":"Cephalalgia"},{"issue":"23","key":"2165_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033874","volume":"102","author":"C Rhyne","year":"2023","unstructured":"Rhyne C, Cohen JM, Seminerio MJ, Carr K, Krasenbaum LJ (2023) Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: a review. Medicine (Baltimore) 102(23):e33874. https:\/\/doi.org\/10.1097\/MD.0000000000033874","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2165_CR39","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/ene.15761","volume":"30","author":"F Schiano di Cola","year":"2023","unstructured":"Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R et al (2023) An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor. Eur J Neurol 30(6):1764\u20131773. https:\/\/doi.org\/10.1111\/ene.15761","journal-title":"Eur J Neurol"},{"issue":"10","key":"2165_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024241288875","volume":"44","author":"P Triller","year":"2024","unstructured":"Triller P, Blessing VN, Overeem LH, Fitzek MP, Hong JB, Lange KS et al (2024) Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: a retrospective cohort study. Cephalalgia 44(10):1\u201311. https:\/\/doi.org\/10.1177\/03331024241288875","journal-title":"Cephalalgia"},{"issue":"17 Suppl 2","key":"2165_CR41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203712","volume":"100","author":"E Casaletto","year":"2023","unstructured":"Casaletto E, Yang QZ, Waters J, Curran J, Lowe A, Yuan H (2023) Real-world effectiveness of eptinezumab after treatment with subcutaneous CGRP monoclonal antibodies in patients with migraine (P12\u201312.009). Neurology 100(17 Suppl 2):4054. https:\/\/doi.org\/10.1212\/WNL.0000000000203712","journal-title":"Neurology"},{"issue":"6","key":"2165_CR42","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s40122-024-00652-z","volume":"13","author":"E Seng","year":"2024","unstructured":"Seng E, Lampl C, Viktrup L, Lenderking WR, Karn H, Hoyt M et al (2024) Patients\u2019 experiences during the long journey before initiating migraine prevention with a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb). Pain Ther 13(6):1589\u20131615. https:\/\/doi.org\/10.1007\/s40122-024-00652-z","journal-title":"Pain Ther"},{"issue":"1","key":"2165_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"issue":"4","key":"2165_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache 64(4):333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache"},{"key":"2165_CR45","doi-asserted-by":"publisher","unstructured":"Medrea I, Cooper P, Langman M, Sandoe CH, Amoozegar F, Hussain WM, et al. (2024) Updated Canadian headache society migraine prevention guideline with systematic review and meta-analysis. Can J Neurol Sci.1\u201323. https:\/\/doi.org\/10.1017\/cjn.2024.285","DOI":"10.1017\/cjn.2024.285"},{"issue":"2","key":"2165_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/head.14069","volume":"61","author":"JS McGinley","year":"2021","unstructured":"McGinley JS, Houts CR, Nishida TK, Buse DC, Lipton RB, Goadsby PJ et al (2021) Systematic review of outcomes and endpoints in preventive migraine clinical trials. Headache 61(2):253\u2013262. https:\/\/doi.org\/10.1111\/head.14069","journal-title":"Headache"},{"issue":"8","key":"2165_CR47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/head.14729","volume":"64","author":"S Ashina","year":"2024","unstructured":"Ashina S, Muenzel EJ, Nicholson RA, Zagar AJ, Buse DC, Reed ML et al (2024) Machine learning identifies factors most associated with seeking medical care for migraine: results of the OVERCOME (US) study. Headache 64(8):1027\u20131039. https:\/\/doi.org\/10.1111\/head.14729","journal-title":"Headache"},{"issue":"23","key":"2165_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200292","volume":"98","author":"C Morris","year":"2022","unstructured":"Morris C, Ross A, Greene K, Irwin S, Wagstaff A, Gelfand A (2022) Outcomes that matter to adolescents with continuous headache due to chronic migraine and their parents: a pilot survey study. Neurology 98(23):e2347. https:\/\/doi.org\/10.1212\/WNL.0000000000200292","journal-title":"Neurology"},{"issue":"18","key":"2165_CR49","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1212\/WNL.0b013e318271f812","volume":"79","author":"MA Arruda","year":"2012","unstructured":"Arruda MA, Bigal ME (2012) Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology 79(18):1881\u20131888. https:\/\/doi.org\/10.1212\/WNL.0b013e318271f812","journal-title":"Neurology"},{"issue":"1","key":"2165_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s10194-024-01923-y","volume":"25","author":"C Fernandes","year":"2024","unstructured":"Fernandes C, Dapkute A, Watson E, Kazaishvili I, Chadzynski P, Varanda S et al (2024) Migraine and cognitive dysfunction: a narrative review. J Headache Pain 25(1):221. https:\/\/doi.org\/10.1186\/s10194-024-01923-y","journal-title":"J Headache Pain"},{"key":"2165_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59050936","author":"M Torrisi","year":"2023","unstructured":"Torrisi M, Corallo F, Lo Buono V, Di Cara M, Grugno R, Lo Presti R (2023) Migraine treatment using Erenumab: can lead to a cognitive and psychological qualitative improvement? Medicina (Kaunas) 59(5). https:\/\/doi.org\/10.3390\/medicina59050936","journal-title":"Medicina (Kaunas)"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02165-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02165-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02165-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:21:02Z","timestamp":1764238862000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02165-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2165"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02165-2","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants gave written informed consent prior to study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CA has served as a consultant for Lilly, Novartis, and Teva and has received honoraria from AbbVie, Amgen, Lilly, Novartis, Teva, and Theranica; he has received royalties from Elsevier for Pain Management Secrets and Raj\u2019s Practical Management of Pain. FAK has received institutional research support from Biohaven, Teva, Marinus, Lundbeck, Supernus, Neurona, and UCB; advisory fees from Eisai, Neurelis, Marinus, Epitel, SK Life Science, AbbVie, Pfizer; honorarium for speaker engagements from Amgen, UCB, SK Life Science, Lundbeck, Allergan, Lilly USA, Pfizer, Impel Pharmaceuticals, AbbVie; honorarium for educational programs from Natus and Stratus; has served on the Louisiana State Medical Advisory Board in a non-paid position and on the board of directors for Deccan Alumni Association of North America in a non-paid position. SPH reports receiving honoraria for speaker engagements from AbbVie. RMS reports no conflicts. DCB has received grant support from Amgen, the US Food and Drug Administration, and the National Headache Foundation; has served as a consultant and received honoraria from Allergan\/AbbVie, Amgen\/Novartis, Biohaven, Collegium, Eli Lilly, Lundbeck, Pfizer, Theranica, and Teva; and has served on the editorial board of Current Pain and Headache Reports. SSB, DA, SFA, SWG, and FP are full-time employees of Lundbeck LLC or H. Lundbeck A\/S.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}